BioHarvest Sciences Inc. (OTCMKTS:CNVCF) Stock In Focus After Appointment Of Gavriel Lambert to the Board of Advisors
A fast-growing biotech firm, BioHarvest Sciences Inc. (OTCMKTS:CNVCF), is actively involved in nutraceuticals and the medicinal cannabis markets. It has developed a patented bio-cell growth platform technology that is able to grow the active and beneficial ingredients in fruit and plants, without the need to grow the plant itself. It can be implemented on an industrial scale, is cost-effective, and guarantees consistency. Moreover, it eradicates the adverse environmental effects associated with conventional agriculture.
Market Stats
On Thursday, CNVCF stock slid 2.36% to $0.1904 with 29K shares, compared to its average volume of 46K shares. The stock moved within a range of $0.1802 – 0.1913 after opening trading at $0.1802.
BioHarvest Sciences Inc. Announces Appointment of Gavriel Lambert to the Board of Advisors
BioHarvest Sciences Inc. on June 30th announced that Gavriel Lambert will serve on its Board of Advisors, with immediate effect. He has almost three decades of expertise in global investment banking, which will be invaluable to the company, going forward.
Back in May 2022, Gavriel has been appointed Head of Consumer Retail Group, EMEA (Europe, Middle East, and Africa) and Co-Head of Global Retail for Jefferies Group. Prior to joining Barclays in 2013, his extensive career (that started in 1995) included holding senior investment banking positions at Solomon Smith Barney, J.P. Morgan, and UBS Securities.
Gavriel has even spearheaded the EMEA Consumer Retail Group for Barclays Plc. from 2016, before the new appointment. He has mentored a team of global professionals with primary coverage responsibility, client development, new business solicitation, transaction origination, and execution for a broad range of retail, consumer, and e-commerce clients. Last but not the least, he has supervised several important M&A and financing transactions.
Ilan Sobel, CEO of BioHarvest, is hopeful that Gavriel’s extensive experience in banking will be helpful as the company seeks to forge new partnerships with the several US and international entities that would enhance the market reach of its products and technology. He is certain that Gavriel will be instrumental in introducing them to the right strategic partners while assisting with the process of reaching the best possible agreements.
Gavriel Lambert, on his part, is thoroughly invested in the power of the Bio-Plant CELLicitation technology developed by BioHarvest. He feels that it is all set to make a considerable impact in the life science-based businesses, and will be lucrative to a vast array of US and international companies covering multiple multi-billion dollar verticals including cannabis, food, and nutraceuticals, biotech, and pharma.
Key Quote
Ilan Sobel, CEO of BioHarvest, said: “Gavriel’s extensive experience in banking comes at an important junction of the company’s evolution as it seeks new partnerships with the several US and international entities that would accelerate the market reach of BHSC’s products and technology. Not only will he help introduce us to the right strategic partners but he will also assist us in the process of achieving the best possible agreements. Furthermore, his capital markets experience will offer us valuable advice as a public company.”
Traders Corner
CNVCF stock is trading below the 20-Day and 50-Day Moving averages of $0.21 and $0.23 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.28.
